REGENXBIO Inc.
RGNXHealthcareNASDAQBiotechnology · Last scanned May 29, 2026
Scan Results
Daily timeframe1 of 4 indicators bullish as of May 28
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. With a market capitalization of $356.2M, it sits in small-cap territory. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
Market Cap
$356.2M
Beta
1.12
P/E (TTM)
—
P/E (Fwd)
-2.73
EPS (TTM)
$-5.60
EPS (Fwd)
$-2.52
ROE
-196.4%
ROA
-38.5%
Cash
$150.5M
Total Debt
$248.4M
Free CF
-$139.0M
52W Change
-22.1%
Annual Financials
Cash vs Debt
On the balance sheet, RGNX has $150.5M in cash with $248.4M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company is burning cash, with free cash flow at -$139.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -196.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $112.7M to $170.4M.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for REGENXBIO Inc. and its sector.